Sponsors (6)
The bill aims to expand and speed access to lower-cost biosimilars and reduce regulatory burden by deeming 351(k) biosimilars interchangeable, trading wider, cheaper access and predictable regulation against reduced product-specific evidence, less pediatric data, narrower labeling, and some short-term market uncertainty.
Patients using biologic therapies will generally get faster and easier access to lower-cost biosimilars because all 351(k) biosimilars are deemed interchangeable, simplifying pharmacy-level substitution.
Biologic manufacturers (including small companies) will face a single licensure pathway without a separate interchangeability application, reducing regulatory burden and likely cutting development costs.
HHS/FDA applicants and health systems will benefit from clearer expectations and more predictable timing because FDA is required to update guidances within 18 months.
Patients (especially those with chronic conditions) may face increased safety or efficacy risks from automatic deemed interchangeability and substitution without product-specific switching data.
Hospitals, clinicians, and payers will likely have less robust switching evidence because manufacturers may have reduced incentives to generate interchangeability data, complicating clinical and formulary decisions.
Children and pediatric clinicians may lack pediatric-specific safety and efficacy data because biosimilars generally will not trigger pediatric study requirements, reducing evidence for pediatric use.
Based on analysis of 2 sections of legislative text.
Automatically deems 351(k) biosimilars interchangeable, removes separate interchangeability submissions, sets a 60‑day transition, revises application and pediatric study rules.
Official title: Improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Introduced June 4, 2025 by Mike Lee · Last progress June 4, 2025
Makes biosimilars licensed under the Biologics Price Competition and Innovation Act automatically treated as interchangeable with their reference products, eliminates a separate interchangeability application pathway, and sets a 60‑day transition window after enactment. Also narrows some application and labeling requirements, preserves existing unexpired exclusivity for any already‑licensed interchangeable product, and requires the Secretary to update related FDA guidances within set timeframes.